Pharma News Intelligence

PharmaNewsIntelligence, a member of the Xtelligent Healthcare Media network, offers in-depth reporting on the pharmaceutical sector. It emphasizes key developments in areas such as drug discovery, development, approval, and marketing. The editorial team at PharmaNewsIntelligence shares valuable insights based on original research and interviews with experts in pharmaceuticals, biotechnology, and biomedical devices.

International

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#11560113

Country

N/A

Articles

Biden administration releases National Heat Strategy

Aug 16, 2024 | pharmanewsintel.com | Veronica Salib

August 16, 2024 - On August 14, 2024, the United States Department of Health and Human Services (HHS) announced the Biden–Harris administration’s National Heat Strategy for 2024–2030, which includes multiple strategies and tactics to address or manage extreme heat by coordinating for planning, response, and resilience. As the global climate crisis continues, the longitudinal impacts of climate change and extreme heat pose a significant healthcare threat.
CMS reaches agreements for lower prices of 10 drugs

Aug 15, 2024 | pharmanewsintel.com | Veronica Salib

August 15, 2024 - After months of anticipation, the United States Centers for Medicare and Medicaid Services (CMS) have announced the finalized agreements on drug price discounts for 10 drugs covered by Medicare. These drug price negotiations were triggered when President Biden signed the Inflation Reduction Act of 2022 into law.
FDA approves first, only treatment for hypoparathyroidism

Aug 14, 2024 | pharmanewsintel.com | Veronica Salib

August 14, 2024 - Acendis Pharma secured the first and only approval for a drug to treat hyperparathyroidism on August 12, 2024. Yorvipath, also known as palopegteriparatide or TransCon PTH, is a prodrug of the parathyroid hormone that regulates and balances calcium and phosphorus in the body. Hypoparathyroidism is a rare condition that affects up to 90,000 people in the United States. According to , the disease is caused when one or more of an individual’s four parathyroid glands are underactive.
FDA approves first nasal spray for anaphylaxis

Aug 13, 2024 | pharmanewsintel.com | Alivia Kaylor

By August 13, 2024 - On August 9, the FDA approved "neffy," the first-ever nasal spray for the emergency treatment of anaphylaxis. This approval represents a significant advancement in managing severe allergic reactions, offering an alternative to traditional epinephrine injections.
40% of Americans say pediatric vaccinations are extremely important

Aug 9, 2024 | pharmanewsintel.com | Veronica Salib

August 09, 2024 - On Wednesday, Gallup, a consulting and global research firm, revealed that fewer Americans are viewing childhood vaccinations as important, with a declining focus on childhood vaccinations among Republicans and Republican-leaning independents. Gallup conducted a survey in July 2024 — which collected data from July 1 to July 21 — asking Americans to report their opinions on childhood vaccination.
CDC updates RSV vaccine recommendations for ages 60 and older

Aug 8, 2024 | pharmanewsintel.com | Veronica Salib

August 08, 2024 - On August 6, 2024, the United States Centers for Disease Control and Prevention updated its recommendations for respiratory syncytial virus (RSV) vaccines in adults ages 60 and older. The updated recommendations are based on a vote from the Advisory Committee on Immunization Practices (ACIP) conducted on June 26, 2024. These recommendations are an update to the previously issued CDC reccomendations in 2023.
FDA issues warning on oysters from Lewis Bay

Aug 6, 2024 | pharmanewsintel.com | Veronica Salib

August 06, 2024 - On August 5, 2024, the United States Food and Drug Administration published a warning advising restaurants, retailers, and consumers to avoid certain oysters from Lewis Bay, Massachusetts. According to the administration, the oysters may be contaminated with Campylobacter jejuni. The FDA warning states that the oysters were harvested from two lease sites in Lewis Bay between July 1, 2024, and July 18, 2024.
HHS announces new policies for underserved communities

Aug 5, 2024 | pharmanewsintel.com | Veronica Salib

August 05, 2024 - The United States Centers for Medicare & Medicaid Services (CMS) under the Department of Health and Human Services (HHS) finalized rulings to support underserved communities, prevent drug shortages, and improve patient safety.
AbbVie acquires Cerevel Therapeutics for $45 per share

Aug 2, 2024 | pharmanewsintel.com | Veronica Salib

August 02, 2024 - On August 1, 2024, AbbVie concluded its acquisition of Cerevel Therapeutics, a clinical-stage neuroscience company, to expand its neuroscience and psychiatric medicine portfolio. The deal was finalized at $45 per share. According to the company’s press release, Cerevel’s pipeline includes multiple neurological and psychiatric drugs in development for various conditions such as schizophrenia, Parkinson’s disease, mood disorders, and more.
Vizient estimates a 3.81% inflation in drug prices in 2025

Aug 1, 2024 | pharmanewsintel.com | Veronica Salib

August 01, 2024 - On July 30, 2024, Vizient issued a press release offering details on its summer 2024 Pharmacy Market Outlook. The outlook estimates that drug price inflation rates for pharmaceuticals will be 3.81% in 2025. Vizient used purchase patterns and data from April 1, 2023, to March 31, 2024, to predict the price of pharmaceuticals between January 1, 2025, and December 31, 2025.